BioCardia, Inc. (BCDA)
NASDAQ: BCDA · Real-Time Price · USD
1.317
+0.007 (0.55%)
Jan 23, 2026, 10:35 AM EST - Market open
BioCardia Employees
As of December 31, 2024, BioCardia had 20 total employees, including 16 full-time and 4 part-time employees. The number of employees did not change compared to the previous year.
Employees
20
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$427,000
Market Cap
13.98M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 20 | 0 | - | 17 | 3 |
| Dec 31, 2023 | 20 | -16 | -44.44% | 16 | 4 |
| Dec 31, 2022 | 36 | 1 | 2.86% | 30 | 6 |
| Dec 31, 2021 | 35 | 6 | 20.69% | 28 | 7 |
| Dec 31, 2020 | 29 | 5 | 20.83% | 24 | 5 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| IO Biotech | 80 |
| CytoMed Therapeutics | 43 |
| Applied Therapeutics | 35 |
| BioLineRx | 28 |
| Tempest Therapeutics | 24 |
| NuCana | 22 |
| Moleculin Biotech | 17 |
| Soligenix | 16 |
BCDA News
- 5 weeks ago - BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA - GlobeNewsWire
- 7 weeks ago - BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress - GlobeNewsWire
- 2 months ago - BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality - GlobeNewsWire
- 2 months ago - BioCardia, Inc. (BCDA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results - GlobeNewsWire
- 2 months ago - BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025 - GlobeNewsWire
- 4 months ago - BioCardia Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 4 months ago - BioCardia Announces Pricing of Up To $12 Million Public Offering - GlobeNewsWire